News
Eli Lilly stock slips after Novo Nordisk trims 2025 forecast; Jaypirca meets endpoint in CLL trial against J&J's Imbruvica, ...
Zacks Investment Research on MSN20d
Can Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?Mounjaro (for type II diabetes) and Zepbound (for obesity) — remains strong. Despite being on the market for less than three years, both drugs have become the company’s key top-line drivers. In the ...
Acknowledging the limits of disease-modifying drugs like Leqembi and Kisunla, companies like Bristol Myers Squibb, Acadia, ...
LLY's $1.3 billion Verve deal marks its third M&A in 2025 as it pushes to diversify across cardiovascular, neuro and cancer therapies.
Zacks Investment Research on MSN7d
How Will Eli Lilly's Oncology Drugs Perform in Q2 Earnings?Eli Lilly LLY offers a diverse range of products that serve multiple therapeutic areas. While the company’s primary focus is ...
Eli Lilly saw its shares jump by 15% on Thursday after unveiling positive results from a clinical trial of its experimental oral drug. REUTERS Lilly’s stock was recently up 14% at $838.80 in ...
Eli Lilly LLY 1.34% agreed to acquire Verve Therapeutics VERV -0.37% for about $1 billion upfront, adding a potential treatment for cardiovascular disease to its portfolio. Under the agreement ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback